公开(公告)号：US11999784B2

公开(公告)日：2024-06-04

申请号：US16451051

申请日：2019-06-25

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Hélène Sicard ,  Renaud Buffet ,  Mathieu Blery

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/28 ,  C07K16/2803 ,  C07K16/3061 ,  G01N33/57407 ,  C07K2317/73 ,  C07K2317/732 ,  G01N2333/70503

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

公开(公告)号：US11572410B2

公开(公告)日：2023-02-07

申请号：US16924288

申请日：2020-07-09

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Carine Paturel ,  Nicolai Wagtmann

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US10577416B2

公开(公告)日：2020-03-03

申请号：US14377274

申请日：2013-02-07

Applicant: INNATE PHARMA, S.A.

Inventor： Mathieu Blery ,  Laurent Gauthier ,  Ivan Perrot ,  Cecile Bonnafous

IPC: C07K16/28 ,  A61K39/00 ,  G01N33/569

Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.

公开(公告)号：US10329348B2

公开(公告)日：2019-06-25

申请号：US15521401

申请日：2015-10-23

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Caroline Soulas ,  Nicolai Wagtmann

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/00

Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

公开(公告)号：US11377492B2

公开(公告)日：2022-07-05

申请号：US16478863

申请日：2018-01-22

Applicant: INNATE PHARMA

Inventor： Nadia Anceriz ,  Mathieu Blery ,  Laurent Gauthier ,  Carine Paturel

IPC: C07K16/30 ,  A61P35/00 ,  C07K16/28 ,  A61K47/68 ,  G01N33/569

Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.

公开(公告)号：US20200299380A1

公开(公告)日：2020-09-24

申请号：US16804705

申请日：2020-02-28

Applicant: Innate Pharma

Inventor： Mathieu Blery ,  Laurent Gauthier ,  Ivan Perrot ,  Cecile Bonnafous

IPC: C07K16/28 ,  G01N33/569

Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.

公开(公告)号：US10676523B2

公开(公告)日：2020-06-09

申请号：US15511792

申请日：2015-09-15

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Carine Paturel ,  Caroline Soulas ,  Nicolaï Wagtmann

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US12037392B2

公开(公告)日：2024-07-16

申请号：US17225160

申请日：2021-04-08

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Carine Paturel ,  Caroline Soulas ,  Nicolaï Wagtmann

IPC: C07K16/30 ,  A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K39/39558 ,  C07K16/2863 ,  C07K16/30 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/76 ,  C07K2317/92 ,  A61K39/39558 ,  A61K2300/00

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US11225519B2

公开(公告)日：2022-01-18

申请号：US16448016

申请日：2019-06-21

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Caroline Soulas ,  Nicolai Wagtmann

IPC: C07K16/28 ,  A61K39/00

Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

公开(公告)号：US10711063B2

公开(公告)日：2020-07-14

申请号：US15511778

申请日：2015-09-15

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Carine Paturel ,  Nicolai Wagtmann

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.